- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05230186
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Laurie Barefoot, APRN
- Numero di telefono: 857-399-9930
- Email: Lbarefoot@tscan.com
Backup dei contatti dello studio
- Nome: Shrikanta Chattopadhyay, MD
- Numero di telefono: 857-399-9472
- Email: Schattopadhyay@tscan.com
Luoghi di studio
-
-
California
-
Los Angeles, California, Stati Uniti, 90033
- Reclutamento
- USC Norris Comprehensive Cancer Center
-
Contatto:
- Xiomara Menendez, RN,
- Numero di telefono: 323-865-0212
- Email: Xiomara.menendez@med.usc.edu
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70124
- Reclutamento
- Ochsner Clinic Foundation
-
Investigatore principale:
- Marc Matrana, MD
-
Contatto:
- Donnalee Trapani, CCRP, CRC
- Numero di telefono: 504-865-0212
- Email: dtrapani@ochsner.org
-
Contatto:
- Rafael Velasquezvalle, Sr. CRC
- Numero di telefono: 504-842-8170
- Email: Rafael.velasquezvalle@ochsner.org
-
Sub-investigatore:
- Lyndsey Buckner Baiamonte, Ph.D
-
-
New Jersey
-
Morristown, New Jersey, Stati Uniti, 07960
- Reclutamento
- Atlantic Health System
-
Investigatore principale:
- Eric Whitman, MD
-
Contatto:
- Maureen Nowakowski, RN
- Numero di telefono: 973-971-7111
- Email: Maureen.nowakowski@atlantichealth.org
-
-
New York
-
New York, New York, Stati Uniti, 10013
- Reclutamento
- Advanced Oncology PC
-
Contatto:
- Kin Lam, MD
- Numero di telefono: 212-941-9020
- Email: kin.lam@rendrcare.com
-
Contatto:
- Isabel Wong, RN
- Numero di telefono: 212-941-9020
- Email: isabelwong2@gmail.com
-
Investigatore principale:
- Kin Lam, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
Cohort Legend: Cohort 1: On-Treatment Responder (Biopsy), Cohort 2: Pre and On-Treatment (Biopsy), Cohort 3: On-Treatment Responder (Surgery), Cohort 4: Post-Treatment Vitiligo, Cohort 5: Post-Treatment Responder (Frozen)
- Study Cohorts 1,2,3 and 5: Known or suspected diagnosis of non-hematological malignancy.
- Age 18 years at time of diagnosis.
- Research Biopsy Study Cohorts 1 and 2: ECOG performance status 0-2.
- Ability to understand and willingness to sign an informed consent document.
- Research Biopsy Study Cohorts 1,2,3 and 5: Patients must be eligible for or currently receiving treatment with immune checkpoint inhibitor (ICI) therapy as determined by the patient's treating oncologist. The treatment regimen may comprise more than one agent but must include at least one ICI drug. Examples of FDA-approved ICI drugs include pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi), cemiplimab (Libtayo), and ipilimumab (Yervoy). Immune-checkpoint inhibitors not on this list may also be used, provided they are FDA-approved.
- Research Biopsy Study Cohorts 1,2,3 and 5: Patients undergoing an on-treatment biopsy must show radiographic regression of one or more lesion, as assessed by the investigator.
- Research Biopsy Study Cohorts 1 and 2: Patients undergoing an on-treatment biopsy must have a cancer lesion that is amenable for biopsy under local anesthesia or moderate sedation per standard procedures. The tumor biopsy must have an acceptable clinical risk, as judged by the investigator.
- Research Biopsy Study Cohorts 1,2,4: Platelet count >50,000 prior to biopsy or per the service performing the biopsy.
- Research Biopsy Study Cohorts 1,2,4: Absolute neutrophil count >1500.
- Research Biopsy Study Cohorts 1,2,4: Must be able to safely hold anticoagulants for 5 days prior to biopsy.
- Research Biopsy Study Cohorts 1,2,4: Not receiving therapeutic anticoagulation at the time of the biopsy. Patients on therapeutic anticoagulation must be able to safely hold anticoagulation for the procedure with an acceptable risk, as judged by the investigator. Patients who are on anticoagulation for clinical reasons and deemed appropriate for biopsy must be OFF anticoagulation prior to biopsy as follows:
i. No warfarin (Coumadin) for 5 days. No low-molecular weight heparin (LMWH; e.g. dalteparin/ Fragmin, enoxaparin/ Lovenox) for 24 hours.
ii. No fondaparinux/ Arixtra for 48 hours. iii. Patients receiving alternative forms of anticoagulation not listed above (e.g., dabigatran, rivaroxaban, apixaban, edoxaban) should consult with the prescribing physician and the service performing the biopsy regarding safety and administration guidelines prior to biopsy. Bleeding risks with these agents should be considered when deciding on whether to perform the biopsy if for research purposes only.
Exclusion Criteria:
Cohort Legend: Cohort 1: On-Treatment Responder (Biopsy), Cohort 2: Pre and On-Treatment (Biopsy), Cohort 3: On-Treatment Responder (Surgery), Cohort 4: Post-Treatment Vitiligo, Cohort 5: Post-Treatment Responder (Frozen)
- Concurrent disease or condition that would make the patient inappropriate for study participation, or any serious medical or psychiatric disorder that would interfere with safety.
- Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
- Research Biopsy Study Cohorts 1,2,4: History of serious or life-threatening allergic reaction to local anesthetics (i.e., lidocaine, xylocaine).
- Pregnant women are excluded because there may be an increased risk to both mother and fetus in the setting of moderate sedation, which is required for biopsies of certain anatomic sites (e.g., liver, lung, bone). Also, ionizing radiation from CT-guided biopsies may pose a risk to the unborn fetus.
- Research Biopsy Study Cohorts 1,2,4: Active cardiac disease, defined as:
i. Uncontrolled or symptomatic angina within the past 3 months. ii. History of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes). Atrial fibrillation with controlled ventricular response on treatment is not an exclusion.
iii. Myocardial infarction < 6 months from study entry. iv. Uncontrolled or symptomatic congestive heart failure. f. Any other condition, which in the opinion of the patient's treating oncologist or the physician performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
On-Treatment Solid Tumor Responder (Tumor Biopsy)
Research tumor tissue biopsy collected at any one time point while responding to ICI therapy (radiographic regression of lesion).
Tumor biopsy and companion blood sample.
|
Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
Altri nomi:
|
Pre and On-Treatment Solid Tumor Responder (Tumor Biopsy)
Tumor tissue collection prior to beginning ICI therapy (optional biopsy).
If and when there is a response to ICI therapy, a second research tumor tissue biopsy is collected.
Tumor biopsy and companion blood sample.
|
Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
Altri nomi:
|
On-Treatment Solid Tumor Responder (Surgical Removal Tumor)
Collection of excess tumor tissue in patients who are responding to ICI therapy and are scheduled for Surgical resection of residual disease.
Excess tissue provided.
|
|
Post-Treatment of patients with Melanoma who develop vitiligo
Up to 5 patients treated for melanoma that develop vitiligo - Skin Tissue Biopsy obtained at any point in time from any skin site with vitiligo (selected sites only).
Tissue biopsy
|
Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
Altri nomi:
|
On-Treatment Responder (Previously Frozen Tumor Tissue)
Previously Cryopreserved Tissue obtained from a Biobank or Tissue Repository, collected from patients when they were responding to ICI Therapy (clinical data required).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Single Cell Sequencing
Lasso di tempo: 3 years
|
Determine, through single-cell sequencing, the TCR repertoire of these tumor and blood samples to identify new targets.
|
3 years
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 200-04
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Tumore solido, adulto
-
AstraZenecaReclutamentoAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, carcinoma gastrico, mammario e ovaricoSpagna, Stati Uniti, Belgio, Regno Unito, Francia, Ungheria, Canada, Corea, Repubblica di, Australia
Prove cliniche su Tumor Biopsy
-
University of TorontoUniversity Health Network, TorontoTerminato
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)ReclutamentoNeoplasie ematologiche | Neoplasia solidaStati Uniti
-
Weill Medical College of Cornell UniversityTerminato
-
AGO Study GroupCancer Research UK; ARCAGY/ GINECO GROUP; Grupo Español de Investigación en Cáncer... e altri collaboratoriCompletatoCancro ovarico | Cancro della tuba di Falloppio | Cancro della cavità peritonealeSpagna, Francia, Danimarca, Belgio, Germania, Austria, Cina, Italia, Corea, Repubblica di, Norvegia, Svezia, Regno Unito
-
Cliniques universitaires Saint-Luc- Université...Université de LiègeReclutamentoFibrosi cistica | BiomarcatoriBelgio
-
Tianjin Medical University Second HospitalSconosciuto
-
Dartmouth-Hitchcock Medical CenterReclutamento
-
NeoDynamics ABReclutamento
-
University of VirginiaCompletato
-
Samsung Medical CenterSconosciuto